Drug Profile
Research programme: psychophysiological insomnia therapeutics - Neurim Pharmaceuticals
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Neurim Pharmaceuticals
- Class
- Mechanism of Action Melatonin receptor agonists; Serotonin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Insomnia
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Insomnia in Israel
- 12 Jun 2008 Preclinical trials in Insomnia in Israel (unspecified route)